Caribou Biosciences — Third Quarter 2026 Earnings Summary

Caribou Biosciences reported a GAAP net loss of $26.6 million for the third quarter of 2026, with total operating expenses of $29.2 million. The company holds $94.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026. On October 6, 2026, the Board of Directors approved a restructuring plan that includes discontinuing clinical trials for vispa-cel and CB-011, along with a substantial workforce reduction. This decision was driven by challenges in securing capital for allogeneic CAR-T cell therapies in the current financing environment.